Examining the Implications of Drug Importation
Full Committee Hearing

Full Committee
Date: Wednesday, July 14, 2004
Time: 10:00 AM

Member Statements


  1. Senator Orrin G. Hatch (R - UT)
  2. Senator Patrick Leahy (D - VT)
  3. Senator Don Nickles (R - OK)
  4. Senator Chuck Grassley (R - IA)
  5. Senator Russ Feingold (D - WI)

Witnesses


Panel I

  1. The Honorable Bernie Sanders
    U.S. Representative
  2. The Honorable Don Nickles
    United States Senator
  3. The Honorable John Breaux
    United States Senator
  4. The Honorable Byron Dorgan
    United States Senator

Panel II

  1. Ms. Elizabeth G. Durant
    Executive Director Of Trade Compliance and Facilitation
    Office of Field Operations at the Bureau of Customs and Border Protection (CBP)
  2. Mr. John Taylor III
    Associate Commissioner for Regulatory Affairs
    U.S. Food and Drug Administration
  3. Mr. William K. Hubbard
    Associate Commissioner for Policy and Planning
    U.S. Food and Drug Administration

Panel III

  1. The Honorable Rudolph W. Giuliani
    Former Mayor of New York City
    Chairman and CEO, Giuliani Partners LLC
  2. Mr. Carmen A. Catizone, M.S., RPh, DPh
    Executive Director/Secretary
    National Association of Boards of Pharmacy Boards
  3. Ms. Joanna Disch, Ph.D.
    Board Member
    AARP
  4. Ms. Kathleen Jaeger
    President and CEO
    Generic Pharmaceutical Association
  5. Dr. Elizabeth A. Wennar M.P.H, D.H.A.
    President and CEO, United Health Alliance of Bennington, VT and Principal, HealthInova of MAnchester, VT
    United Health Alliance
  6. Professor Stephen W. Schondelmeyer, Ph.D.
    Professor of Pharmaceutical Economics
    University of Minnesota College of Pharmacy